Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: Evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial

V. Joly, M. Moroni, E. Concia, A. Lazzarin, B. Hirschel, J. Jost, F. Chiodo, Z. Bentwich, W. C. Love, D. A. Hawkins, E. G L Wilkins, A. J. Gatell, N. Vetter, C. Greenwald, W. W. Freimuth, W. De Cian, D. Cooper, J. Hoy, D. Shaw, A. StreetE. Tschachler, N. Vetter, N. Clumeck, J. Demonty, B. Vandercam, L. Mathiesen, G. Sheehan, E. Auvergnat, G. Bouvet, G. Delzant, V. Joly, J. Kisterman, [No Value] Lafeuillade, J. Lang, G. Lepeu, P. Massip, F. Raffi, K. Arasteh, H. Busch, M. Hartman, H. Jablonowski, H. Jaeger, A. Mutz, H. Rasokat, J. Rockstroh, B. Ruf, I. Schedel, W. Stille, D. Banhegyi, Z. Bentwitch, I. Yust, F. Chiada, E. Concia, A. Lazzarin, M. Moroni, M. Piazza, M. Soranzo, J. Borleffs, G. Schrey, C. Tannapel, A. Horban, A. Sonnerborg, B. Clotet, A. Gatell, J. Lahoz, M. Leal, B. Hirschel, J. Jost, I. Ahmed-Jushuf, C. Bradbeer, R. Brettle, D. Hawkins, W. Love, A. Pozniak, K. Radcliffe, S. Tchamouroff, E. Wilkins

Research output: Contribution to journalArticlepeer-review

Abstract

We compared the activity of delavirdine (DLV) plus zidovudine (AZT) (n = 300) with that of AZT (n = 297) against human immunodeficiency virus type 1 in a randomized, double-blind, placebo-controlled trial. DLV exerted a transient antiviral effect, and mutations for resistance to DLV were found in more than 90% of subjects at week 12. The K103N mutation, which confers nonnucleoside reverse transcriptase inhibitor cross-resistance, was found in 85% of the patients.

Original languageEnglish
Pages (from-to)3155-3157
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Volume44
Issue number11
DOIs
Publication statusPublished - 2000

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: Evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial'. Together they form a unique fingerprint.

Cite this